PMID- 30139310
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20181211
IS  - 1607-8454 (Electronic)
IS  - 1024-5332 (Linking)
VI  - 24
IP  - 1
DP  - 2019 Dec
TI  - Comparative study of bone marrow and blood plasma levels of IL-2 in aplastic 
      anaemia and their relationship with disease severity.
PG  - 84-88
LID - 10.1080/10245332.2018.1512391 [doi]
AB  - OBJECTIVES: Interleukin-2 (alias: IL-2, TCGF, Lymphokine), a type of interleukin, 
      is also a potent signalling molecule in the signalling cascade of the 
      immune-mediated activation of T Lymphocytes leading to the destruction of 
      haematopoietic stem cell (HSC) which is the basis of acquired aplastic anaemia 
      (AAA). The objective was to study the association of IL-2 in the bone marrow 
      plasma (BMP) and peripheral blood plasma (PBP) in AAA patients. METHODS: A total 
      of 52 BMP and PBP-paired samples (both from the same patients) was collected from 
      the confirmed AAA patients and 10 healthy individuals. The level of IL-2 was 
      measured by the quantitative enzyme-linked immunosorbent assay (ELISA). The 
      Mann-Whitney U test was used for statistical analysis. RESULTS: Significantly 
      increased level of IL-2 was observed in the BMP than PBP of AAA patients. The 
      level of IL-2 in PBP and BMP was found to be very low in the control cases. 
      Considerably increased levels of IL-2 were found in the PBP and BMP of AAA 
      patients as compared to controls (48.54 +/- 21.89 vs. 1.99 +/- 1.25 
      p-value < 0.00001) and (75.33 +/- 41.9 vs. 3.12 +/- 1.82; p-value < 0.00001) 
      respectively. Among these patients, the IL-2 levels were higher in patients with 
      Very Severe Aplastic Anaemia (VSAA) and Severe Aplastic Anaemia (SAA) than those 
      with Non-severe Aplastic Anaemia (NSAA) in the PBP (65.6 +/- 23.61 vs. 
      31.72 +/- 7.64; p-value 0.00338) and (45.37 +/- 16.25 vs. 31.72 +/- 7.64; p-value 
      0.01468) respectively. Again the IL-2 levels were higher in patients with VSAA 
      and SAA than those with NSAA in the BMP (115.01 +/- 38.91 vs. 38.32 +/- 19.49; 
      p-value < 0.00001) and (66.44 +/- 23.34 vs. 38.32 +/- 19.49; p-value 0.0006). The 
      IL-2 level was higher in VSAA than SAA in PBP (65.6 +/- 23.61vs. 45.37 +/- 16.25; 
      p-value 0.0114) and BMP (115.01 +/- 38.91 vs. 66.44 +/- 23.34; p-value 0.00044). 
      CONCLUSION: This study emphasized on the bone marrow and blood plasma levels of 
      IL-2 in aplastic anaemia and their relationship with disease severity. The 
      results indicate towards the fact that IL-2 may have an important association 
      with the marrow failure of AAA patients and thus can help in disease development. 
      Further study is necessary for better understanding.
FAU - De, Rajib
AU  - De R
AD  - a Haematology , Nil Ratan Sircar Medical College and Hospital , Kolkata , India.
FAU - Dutta, Atreyee
AU  - Dutta A
AD  - b Genetics , Vivekananda Institute of Medical Sciences , Kolkata , India.
FAU - Dolai, Tuphan Kanti
AU  - Dolai TK
AD  - a Haematology , Nil Ratan Sircar Medical College and Hospital , Kolkata , India.
FAU - Ghosh, Kakoli
AU  - Ghosh K
AD  - b Genetics , Vivekananda Institute of Medical Sciences , Kolkata , India.
FAU - Halder, Ajanta
AU  - Halder A
AD  - b Genetics , Vivekananda Institute of Medical Sciences , Kolkata , India.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
DEP - 20180823
PL  - England
TA  - Hematology
JT  - Hematology (Amsterdam, Netherlands)
JID - 9708388
RN  - 0 (IL2 protein, human)
RN  - 0 (Interleukin-2)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anemia, Aplastic/*blood/pathology
MH  - Bone Marrow/*metabolism/pathology
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Interleukin-2/*blood
MH  - Male
MH  - Middle Aged
MH  - *Severity of Illness Index
OTO - NOTNLM
OT  - Interleukin-2
OT  - acquired aplastic anaemia
OT  - blood plasma
OT  - bone marrow plasma
OT  - destruction of stem cell
OT  - disease severity of aplastic anaemia
OT  - enzyme-linked immunosorbent assay
EDAT- 2018/08/25 06:00
MHDA- 2018/12/12 06:00
CRDT- 2018/08/25 06:00
PHST- 2018/08/25 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2018/08/25 06:00 [entrez]
AID - 10.1080/10245332.2018.1512391 [doi]
PST - ppublish
SO  - Hematology. 2019 Dec;24(1):84-88. doi: 10.1080/10245332.2018.1512391. Epub 2018 
      Aug 23.